0001003642-18-000077.txt : 20180508
0001003642-18-000077.hdr.sgml : 20180508
20180508160659
ACCESSION NUMBER: 0001003642-18-000077
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180504
FILED AS OF DATE: 20180508
DATE AS OF CHANGE: 20180508
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BISARO PAUL
CENTRAL INDEX KEY: 0001237253
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34263
FILM NUMBER: 18814563
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Impax Laboratories, LLC
CENTRAL INDEX KEY: 0001003642
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 650403311
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 30831 HUNTWOOD AVENUE
CITY: HAYWARD
STATE: CA
ZIP: 94544
BUSINESS PHONE: 510-240-6000
MAIL ADDRESS:
STREET 1: 30831 HUNTWOOD AVENUE
CITY: HAYWARD
STATE: CA
ZIP: 94544
FORMER COMPANY:
FORMER CONFORMED NAME: IMPAX LABORATORIES INC
DATE OF NAME CHANGE: 19991227
FORMER COMPANY:
FORMER CONFORMED NAME: GLOBAL PHARMACEUTICAL CORP \DE\
DATE OF NAME CHANGE: 19951117
4
1
wf-form4_152581000589975.xml
FORM 4
X0306
4
2018-05-04
1
0001003642
Impax Laboratories, LLC
IPXL
0001237253
BISARO PAUL
C/O IMPAX LABORATORIES, INC.
30831 HUNTWOOD AVENUE
HAYWARD
CA
94544
1
1
0
0
President and CEO
Stock Option (Right to Buy)
12.7
2018-05-04
4
D
0
850000
D
2027-03-27
Common Stock
850000.0
0
D
Options disposed of pursuant to the terms of the Business Combination Agreement, dated as of October 17, 2017, by and among Impax Laboratories, Inc., Atlas Holdings, Inc. ("Holdco"), K2 Merger Sub Corporation and Amneal Pharmaceuticals LLC, as amended by Amendment No. 1, dated as of November 21, 2017, and Amendment No. 2, dated as of December 16, 2017 (the "BCA"), according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock of Holdco equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA at a per-share exercise price equal to the per-share exercise price of such Option.
The filing of this Statement shall not be construed as an admission (a) that the person filing this Statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this Statement, or (b) that this Statement is legally required to be filed by such person.
/s/ Wenchi Liu, by Power of Attorney
2018-05-08